Suppr超能文献

喉鳞状细胞癌颈部转移的预测因素。迈向综合临床分子分类

Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification.

作者信息

Almadori G, Bussu F, Paludettii G

机构信息

Institute of Otolaryngology, Sacred Heart Catholic University, Rome, Italy.

出版信息

Acta Otorhinolaryngol Ital. 2006 Dec;26(6):326-34.

Abstract

Our group has 25 years' experience in the use of molecular predictive markers in head and neck cancer, on a large patient population, enrolled from a single institution, with a long follow-up, and, most of all, homogeneous regarding histology (squamous cell carcinoma) and site (larynx). Among the most frequent malignancies in the US, cancers of the larynx and uterine corpus are the only types not showing an increase in 5-year Survival Rates over the last 30 years. As far as concerns laryngeal squamous cell carcinoma, we can identify several potential reasons for this failure, the most relevant probably lies in the neck. For this reason, a key issue in laryngeal oncology is to assess metastatic potential of squamous cell carcinoma at diagnosis. Nevertheless, the combination of clinical and histological parameters is not sufficiently reliable in the prediction of lymph node metastases. Molecular characterization, by the study of molecular predictive factors, is a clinical approach aimed to define homogeneous subgroups for clinical metastatic behaviour. Defining invasiveness by means of studies on selected molecular markers (among which the most reliable is probably Epidermal Growth Factor Receptor (EGFR)) may be useful in the choice of the most appropriate treatment on both T and on N.

摘要

我们团队在头颈部癌分子预测标志物的应用方面拥有25年经验,研究对象为来自单一机构的大量患者群体,随访时间长,最重要的是,组织学(鳞状细胞癌)和部位(喉)均保持一致。在美国最常见的恶性肿瘤中,喉癌和子宫体癌是过去30年中仅有的5年生存率未出现上升的类型。就喉鳞状细胞癌而言,我们可以找出导致这种情况的几个潜在原因,其中最关键的可能在于颈部。因此,喉肿瘤学中的一个关键问题是在诊断时评估鳞状细胞癌的转移潜能。然而,临床和组织学参数的结合在预测淋巴结转移方面并不足够可靠。通过研究分子预测因子进行分子特征分析,是一种旨在为临床转移行为定义同质亚组的临床方法。通过对选定分子标志物(其中最可靠的可能是表皮生长因子受体(EGFR))的研究来定义侵袭性,可能有助于在T和N方面选择最合适的治疗方法。

相似文献

3

引用本文的文献

2
Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC).
Diagn Pathol. 2019 May 28;14(1):49. doi: 10.1186/s13000-019-0823-3.
3
Micro-ribonucleic acid expression profiling and bioinformatic target gene analyses in laryngeal carcinoma.
Onco Targets Ther. 2014 Apr 5;7:525-33. doi: 10.2147/OTT.S59871. eCollection 2014.
6
Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer.
Med Oncol. 2013 Mar;30(1):333. doi: 10.1007/s12032-012-0333-6. Epub 2012 Dec 27.
7
Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients.
PLoS One. 2012;7(7):e40704. doi: 10.1371/journal.pone.0040704. Epub 2012 Jul 16.
8
MYCT1-TV, a novel MYCT1 transcript, is regulated by c-Myc and may participate in laryngeal carcinogenesis.
PLoS One. 2011;6(10):e25648. doi: 10.1371/journal.pone.0025648. Epub 2011 Oct 5.
9
MMP-2 expression in 102 patients with glottic laryngeal cancer.
Eur Arch Otorhinolaryngol. 2012 Feb;269(2):639-42. doi: 10.1007/s00405-011-1625-8. Epub 2011 Jun 11.

本文引用的文献

1
Neck dissection: then and now.
Auris Nasus Larynx. 2006 Dec;33(4):365-74. doi: 10.1016/j.anl.2006.06.001. Epub 2006 Aug 4.
2
Cancer statistics, 2006.
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. doi: 10.3322/canjclin.56.2.106.
3
Neck dissection: past, present and future?
J Laryngol Otol. 2006 Feb;120(2):87-92. doi: 10.1017/S0022215105004512. Epub 2005 Nov 25.
4
Management of the N0 neck--reference or preference.
Oral Oncol. 2006 Feb;42(2):115-22. doi: 10.1016/j.oraloncology.2005.04.006. Epub 2005 Jun 24.
5
Elective and therapeutic selective neck dissection.
Oral Oncol. 2006 Jan;42(1):14-25. doi: 10.1016/j.oraloncology.2005.03.009. Epub 2005 Jun 23.
6
7
What is the treatment of choice for Tl squamous cell carcinoma of the larynx?
J Laryngol Otol. 2004 Oct;118(10):747-9. doi: 10.1258/0022215042450760.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验